ASCO Annual Meeting

Patients with HR+, HER2–, Early Breast Cancer Experienced Survival Improvement with Verzenio Plus Endocrine Therapy

June 3rd 2023, 6:00pm

Article

Findings from the monarchE trial presented at ASCO showed that for patients with hormone receptor–positive, HER2-negative, high-risk, early breast cancer, Verzenio provided “consistent treatment benefit.”

Radium-223 Safe and Effective to Treat Metastatic Castration-Resistant Prostate Cancer

June 3rd 2023, 4:00pm

Article

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.

After Approval, Tecartus Continues to Impress in B-Cell ALL

June 3rd 2023, 2:00pm

Article

The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.

Avastin Regimen Improves Survival in Ovarian Cancer, Including Some HRD-Positive Tumors

June 3rd 2023, 12:00pm

Article

A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.

Obe-cel Leads to Deep, Durable Responses in B-Cell ALL

June 3rd 2023, 12:19am

Article

Three-fourths of patients with relapsed/refractory B-cell acute lymphoblastic leukemia experienced complete responses — which tended to be durable — when treated with the CAR-T cell therapy, Obe-cel.

Simple Hysterectomy ‘the New Standard’ for Low-Risk, Early Cervical Cancer

June 2nd 2023, 9:00pm

Article

Results of the Canadian Cancer Trials Group CX.5/SHAPE trial could lead to surgical de-escalation among patients with cervical cancer.

Kisqali Plus Endocrine Therapy Improves Early Breast Cancer Outcomes

June 2nd 2023, 1:00pm

Article

Adding Kisqali to endocrine therapy tended to improve the amount of time patients with HR-positive, HER2-negative early breast cancer lived before their disease became invasive.

Frontline Keytruda Plus Chemo, Regardless of Avastin, Provides Survival Benefit in Cervical Cancer

May 29th 2023, 6:00pm

Article

The benefit obtained from Keytruda plus chemotherapy in patients with persistent, recurrent or metastatic cervical cancer occurred regardless of whether they also received Avastin.

Medicaid Expansion Boosts Pancreatic, Gastric Cancer Survival, Thereby Reducing Disparities

May 26th 2023, 9:00pm

Article

States that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

May 25th 2023, 10:00pm

Article

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.